Well the post posited that Roche purchasing this company would be a major negative for REGN. To my mind that would only be the case if Roche managed somehow to prevent the use of the new drug with Eylea. It is true that Lucentis/Fovista has a head start by virtue of being tested together, but long term Eylea/Fovista should work just as well if they can run the appropriate trials.
News 
Market Data 
Discover 
AI
